Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Abstract

Abstract:The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofl uorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientifi c and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.

Inhalable Microparticulate System for Tuberculosis: An Updated Review

“…The Impact is most common way that dry powder inhalers and metered dose inhalers put down their Medicine (MDI). 12…”

Liquid Perfluorochemicals as Flexible and Efficient Gas Carriers Applied in Bioprocess Engineering: An Updated Overview and Future Prospects

“…The form of liquid PFC-based emulsions depends on the way of its bioengineering application. Two main lines of research are being actively pursued: (i) PFC-inwater emulsions for in vivo intravascular oxygen delivery (known as perfluorinated temporary blood substitutes) (Krafft et al, 2003;Riess, 2006b;Vasquez et al, 2013), as storage-media during organ transplantation procedures (Bezinover et al, 2014;Maillard et al, 2008;Terai et al, 2010), currently under development for treatment of traumatic brain and spinal cord injury (Spiess, 2009) as well as in decompression sickness therapy (Randsoe and Hyldegaard, 2009), and (ii) water-in-PFC reverse emulsions for pulmonary drug delivery (Courrier et al, 2004;Smoła et al, 2008), targeted emulsions for diagnosis and therapy (Kaufmann and Lindner, 2007;Lanza and Wickline, 2001;Martin and Dayton, 2013), as well as valuable research tool used in polymerisation technology (Chen et al, 2010;Zetterlund et al, 2008).…”

A study on development of fingerprint powders using natural sources for latent fingerprint visualization on non-porous surfaces

“…Modern fingerprint powders represent substantially fewer health dangers because they are primarily formed of organic components (Balan V, Mihai CT, et al, 2019) [11] however, there is concern that minute particles inside the fingerprint powders may be breathed, resulting in the development of lung disorders after extended exposure. Smaller particle size powders, such as fluorescent powders or the newer nano powders, are more dangerous since they can reach and settle deep into the lungs (Smola M, Vandamme T, et al, 2008) [12] . Individuals who frequently use these powders should thus take the required precautions to reduce the risk of respiratory illness, such as working in a fume hood or wearing a mask.…”